Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 12/17/21 | 8-K | Current report filing |
|
   |
5 |
| 12/17/21 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
82 |
| 10/07/21 | 8-K | Current report filing |
|
|
2 |
| 08/31/21 | 8-K | Current report filing |
|
|
2 |
| 08/25/21 | 8-K | Current report filing |
|
|
20 |
| 08/23/21 | 424B4 | Prospectus filed pursuant to Rule 424(b)(4) |
|
12 | |
| 08/19/21 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 08/19/21 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 08/19/21 | EFFECT | Notice of Effectiveness |
|
1 | |
| 08/19/21 | 8-K | Current report filing |
|
|
2 |
